BRTX - CIK 0001505497
BioRestorative Therapies, Inc. trades as BRTX. In its fiscal 2025 annual report the company posted revenue of $359.70K, down 10.3% from the prior year and net income of -$14.24M. This page tracks BioRestorative Therapies, Inc. through 735 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years BioRestorative Therapies, Inc.'s revenue grew from $36.35K to $359.70K, a compound annual growth rate of 29.0%. Net profit margin expanded from -23755.4% to -3959.4% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-14 |
| Major company event | 8-K | 2026-05-01 |
| 424B3 | - | 2026-04-30 |
| EFFECT | - | 2026-04-28 |
| POS AM | - | 2026-04-27 |
| Major company event | 8-K | 2026-04-23 |
| POS AM | - | 2026-04-20 |
The largest companies sharing BioRestorative Therapies, Inc.'s SEC industry classification (services-misc health & allied services, nec).
BioRestorative Therapies, Inc. reported revenue of $359.70K for fiscal year 2025, a decrease of 10.3% year over year.
In its latest fiscal year BioRestorative Therapies, Inc. reported a net loss of $14.24M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.